JPH0720854B2 - Oral composition - Google Patents

Description

TECHNICAL FIELD The present invention relates to a composition for oral cavity which has a high effect of suppressing plaque formation and an excellent effect of preventing dental caries and periodontal disease.

Problems to be Solved by Conventional Techniques and Inventions Plaque is a metabolite of bacteria such as dextran, bacterial groups, saliva components, food residues, etc. deposited on teeth,
Organic acids produced by oral bacteria in dental plaque and certain proteases are considered to be one of the main causes of dental caries and periodontal disease. That is, dental plaque provides a place of activity for bacteria that cause caries and periodontal disease, and also a place where the acids produced by these bacteria and the enzymes that cause tissue destruction are retained for a long time.

Therefore, for the prevention and treatment of dental caries and periodontal disease, it is effective to suppress the formation of plaque or decompose and remove it. Therefore, many studies have been made on this point.

Glucans such as dextran produced by Streptococcus mutans using sucrose as a substrate are known to play an important role in the formation of plaque, but plaque formation by such Streptococcus mutans is known. In order to suppress it, it has been conventionally practiced to incorporate a bactericide into the oral composition. However, blending a bactericide at a high concentration is not preferable in terms of safety.

Further, dextranase is known as an active ingredient that suppresses the formation of plaque due to Streptococcus mutans, but dextranase has a limited blending amount in the oral composition.

Therefore, there has been a demand for a composition for the oral cavity, which has a higher effect of suppressing the formation of plaque.

The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an oral composition that has an excellent effect of suppressing plaque formation and is highly safe in use.

Means and Actions for Solving Problems That is, the present inventors have conducted intensive studies on active ingredients excellent in suppressing and decomposing plaque, and as a result, conventionally, an interface for enhancing foamability and detergency When N-palmitoyl sarcosine salt or N-myristoyl sarcosine salt known as an active agent is used in combination with dextranase, they act synergistically and are found to exhibit a remarkable plaque suppressing effect, The present invention has been completed.

Conventionally, by using N-long-chain acylamino acid containing N-lauroyl sarcosine salt or a salt thereof together with a higher alcohol sulfate or a salt thereof in a specific range, inactivation of dextranase can be prevented and dextranase can be prevented. It is known that Nase is stably retained in the oral composition (JP-A-56-123910), but specifically, N-palmitoyl sarcosine salt or N-myristoyl sarcosine salt and dextranase are specifically mentioned. There is no disclosure of using and together. The combined use of N-lauroyl sarcosine salt with dextranase is described in this publication, but dextranase and N-
Even if it is used in combination with lauroyl sarcosine salt, synergistic effect on plaque suppression is not exhibited as shown in the experimental example described later, but N-palmitoyl sarcosine salt and N
-When myristoyl sarcosine salt is used in combination with dextranase, it shows a remarkable synergistic effect and has an excellent plaque suppressing effect, which is a new finding by the present inventors.

Hereinafter, the present invention will be described in more detail.

The oral composition according to the present invention is prepared and applied as a toothpaste, a powdered toothpaste, a toothpaste such as a liquid toothpaste, a mouthwash, a mouthwash tablet, a gum massage cream, a chewing gum, and a troche. Palmitoyl sarcosine salt and / or N-myristoyl sarcosine salt and dextranase are used together as an active ingredient for suppressing plaque formation.

Here, as the N-palmitoyl sarcosine salt or the N-myristoyl sarcosine salt, an alkali metal salt such as sodium salt is preferably used.

Moreover, the compounding quantity of N-palmitoyl sarcosine salt and / or N-myristoyl sarcosine salt is 0.00 of the whole composition.
It is preferably set to 05 to 5% (% by weight, the same applies hereinafter), particularly 0.001 to 1.5%. In the present invention, N-palmitoyl sarcosine salt and / or N-myristoyl sarcosine salt are thus used, and this is used in combination with dextranase, which results in a significant synergistic effect of suppressing plaque. Other N-acyl sarcosine salts, that is, those having an acyl group having 12 or less carbon atoms, such as N-
Lauroyl sarcosine salts do not have a synergistic effect of suppressing plaque even when used in combination with dextranase, and those having an acyl group having 18 or more carbon atoms have poor solubility, and thus both achieve the object of the present invention. I can't.

In addition, dextranase can be used regardless of microbial origin as long as it has α-1,6-glucosidase activity. The blending amount is, for example, 0.001 to 2% of the entire composition when 1 million units / g of dextranase is used,
It is particularly preferably 0.01 to 1%.

In the present invention, N-palmitoyl sarcosine salt and / or
Alternatively, the compounding ratio of N-myristoyl sarcosine salt and dextranase is preferably 1: 400 to 200: 1 by weight ratio, and by using together in this range, synergistic plaque inhibitory action of both is achieved. Definitely demonstrated.

In addition to the above components, the oral composition of the present invention may contain appropriate components depending on the type of the oral composition.

For example, in the case of toothpaste, an abrasive such as dicalcium phosphate, calcium carbonate, calcium pyrophosphate, insoluble sodium metaphosphate, amorphous silica, crystalline silica, aluminosilicate, aluminum oxide, aluminum hydroxide, or resin, Binders such as carboxymethyl cellulose, hydroxyethyl cellulose, alginate, carrageenan, gum arabic and polyvinyl alcohol, thickeners such as polyethylene glycol, sorbitol, glycerin and propylene glycol, and optionally N-palmitoyl sarcosine salt and N-myristoyl. Surfactants other than sarcosine salts, such as sodium lauryl sulfate, sodium dodecylbenzene sulfonate, hydrogenated coconut fatty acid monoglyceride sodium monosulfate, lauryl sulfone Sodium acid, N-acyl glutamate, sucrose fatty acid ester and the like, and saccharin sodium, stevioside, neohesperidyl dihydrochalcone, glycyrrhizin, perillartine, p-methoxycinnamic aldehyde, isomaltose, palatinose, sweeteners such as coupling sugar, etc., Components such as fragrances and preservatives are mixed with water, and the mixture is manufactured according to a conventional method.
Further, in mouthwashes such as mouthwash and the like, components suitable for the properties of the product are appropriately mixed.

In the oral composition of the present invention, chlorhexidine salt, lytic enzyme, mutanase, sorbic acid, alexidine, hinokitiol, cetylpyridinium chloride,
Active ingredients such as alkylglycine, alkyldiaminoethylglycine salt, allantoin, ε-aminocaproic acid, tranexamic acid, azulene, vitamin E, water-soluble primary or secondary phosphates, quaternary ammonium compounds, sodium chloride are further added. You can also do it.

Effect of the Invention The oral composition of the present invention exerts an excellent plaque formation suppressing effect by the synergistic action of these components by using N-palmitoyl and / or N-myristoyl sarcosine salt and dextranase in combination. Therefore, it is highly effective in preventing dental caries and periodontal disease.

Next, the effects of the present invention will be specifically shown by experimental examples.

[Experimental example]

The effect of suppressing plaque formation by the combined use of dextranase and N-acyl sarcosine salt was examined by the following method.

Experimental method Samples of the types and amounts shown in Table 1 were dissolved in 4 ml of 1% sucrose-added Brain Heart Infusion Medium, which was placed in a test tube, and Brain Heart Infusion Medium was added to this tube. In advance at 37 ℃
After inoculating Streptococcus mutans bacteria anaerobically cultured for 18 hours, tilt the test tube at 30 degrees and anaerobically culture for 18 hours,
Measure the amount of bacteria attached to the wall of the test tube. As a control, the same experiment was carried out using a medium to which no sample was added. Ask for. The results are shown in Table 1.

From the results in Table 1, it was confirmed that the plaque formation by Streptococcus mutans was synergistically suppressed when dextranase and N-palmitoyl or N-myristoyl sarcosine salt were used in combination. In contrast,
When the N-lauroyl sarcosine salt was used, there was almost no synergistic effect.

Examples will be shown below.

[Example 1] Toothpaste dicalcium phosphate 50% sorbit 20 Carrageenan 1 Saccharin sodium 0.1 Sodium laurin sulfate 1.2 Lauryl diethanolamide 0.5 Fragrance 0.8 Dextranase (800,000 units / g) 2 N-myristoyl sarcosine sodium 0.5 Chlorhexidine gluconate 0.01 Water Residual 100% [Example 2] Toothpaste Aluminum hydroxide 44% Sorbit 30 Carrageenan 1 Saccharin sodium 0.1 Sodium laurin sulfate 1.2 Lauryl diethanolamide 0.5 Perfume 0.8 Dextranase (800,000 units / g) 2 N-myristoyl monkey Cocin sodium 0.25 N-palmitoyl sarcosin sodium 0.25 Sodium monofluorophosphate 0.76 Water Residual 100% [Example 3] Toothpaste Aluminum hydroxide 44% Solbit 30 Carrageenan 1 Saccharin sodium 0.1 Sodium lauryl sulfate 1.2 Lauryl diethanolamide 0.5 Perfume 0.8 Dextranase (800,000 units / g) 2 N-myristoyl sarcosine sodium 0.5 Cetylpyridinium chloride 0.01 Sodium monofluorophosphate 0.76 Water residual 100% [Example 4] Toothpaste dicalcium phosphate 50% Calcium carbonate 25 Sorbit 10 Sodium lauryl sulfate 1 Sodium saccharin 0.1 Perfume 1 Dextranase (1 million units / g) 1 N-myristoyl sarcosine sodium 0.5 Water residual 100% [Example 5] Washing Oral formulation Ethyl alcohol 20% α-Olefin sulfonate 0.5 Sodium saccharin 0.1 Perfume 1 Polyoxyethylene sorbitan fatty acid ester 1.5 Lauryl diethanolamide 0.5 Dextranase (500,000 units / g) 3 N-myristoyl sarcosine sodium 0.2 Water Residual 100% Dilute 10 times with water before use.

[Example 6] troche gum arabic 6% glucose 36 flavor 1 palatinose 36 dextranase (1 million units / g) 1 N-myristoyl sarcosine sodium 0.1 water balance 100% [Example 7] chewing gum gum base 20% carbonic acid Calcium 2 Water candy 15 Powder sugar 60 Perfume 1 Dextranase (1 million units / g) 1 N-myristoyl sarcosin sodium 0.1 Water Residual 100%

 ─────────────────────────────────────────────────── ─── Continuation of the front page (56) References JP-A-56-123910 (JP, A) JP-A-56-118012 (JP, A) JP-A-59-152314 (JP, A)

Claims (2)

[Claims] 1. An oral composition comprising a combination of N-palmitoyl sarcosine salt and / or N-myristoyl sarcosine salt and dechitoslanase as an active ingredient for suppressing plaque. 2. The amount of N-palmitoyl sarcosine salt and / or N-myristoyl sarcosine salt incorporated in the entire composition
The oral composition according to claim 1, which is 0.0005 to 5% by weight.